Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...
March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Within the iShares Nasdaq Biotechnology ETF (IBB), the biotechnology and pharmaceutical subgroups have a combined weight of ~97.5% of IBB’s portfolio. The moving average provides investors with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback